Catalent today announced that it had signed a commercial supply agreement with Phathom Pharmaceuticals for its lead compound, vonoprazan, which is a novel, orally active-potassium competitive acid blocker (P-CAB).

Catalent today announced that it has reached an agreement to acquire Bettera Holdings, LLC, a major manufacturer in the high-growth gummy, soft chew, and lozenge segments of the nutritional supplements market, for $1 billion.

Catalent today announced the appointment of Harold A. Jenkins III, as General Manager of its recently expanded Philadelphia facility, the company’s North American center of excellence for clinical supply packaging.

Catalent has signed a commercial supply agreement with Edenbridge Pharmaceuticals, for a novel formulation of glycopyrrolate using Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) delivery technology intended for use as adjunctive therapy in the treatment of patients with peptic ulcer.

Catalent announced that, effective July 1, 2021, 97% of its electricity usage across its global network is being procured from renewable energy sources such as wind, solar, hydroelectric, and biomass.

DisperSol Technologies and Catalent today announced a strategic manufacturing collaboration to accelerate the development of multiple DisperSol pharmaceutical products.

Catalent today announced the launch of its new OptiDose® Design Solution, a comprehensive assessment of your molecule, patient, and market, to help drive the dose design decision-making process and create successful treatments.

Leveraging Catalent’s proven GPEx® expression platform in a glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line system, GPEx Lightning combines innovative technologies to further shorten drug substance development timelines.

Catalent today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.